New hope for teens with stubborn bone cancer: drug combo trial launched
NCT ID NCT05395741
First seen May 07, 2026 · Last updated May 25, 2026 · Updated 3 times
Summary
This study tests a drug called regorafenib in 30 teens (ages 9-21) with Ewing sarcoma or osteosarcoma that has come back or not responded to standard therapy. The goal is to see if the drug can improve how long they live without the cancer growing, while also checking for side effects. The approach combines advanced molecular diagnostics to tailor treatment for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, 02-781, Poland
-
the Institute of Mother and Child
Warsaw, 01-211, Poland
Conditions
Explore the condition pages connected to this study.